What BNC KOREA does

BNC KOREA (한국비엔씨, Inc.) is a Korean bio-venture founded in August 2007 and listed on KOSDAQ since 2019 (previously KONEX from 2015). The company develops, manufactures, and commercializes medical devices, pharmaceuticals, and cosmeceuticals based on biomaterials processing technologies—principally hyaluronic acid (HA) and collagen. Its product portfolio spans HA-based dermal fillers (Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Juvegel HA+PN composite), skin boosters (Cutegel Hydro, S-DNA, H-DNA, AQUABIEN HYDRO PURE, CELLABIEN I GLOWY), the botulinum toxin type A pharmaceutical BIENOX, the HA-based anti-adhesion barrier gel Hibarry for spinal surgery, collagen-based wound dressings and tissue supplements (GentaQ, Collapleo, Collapleo Plus), and the I.st premium cosmeceutical skincare brand.

The company operates a vertically integrated manufacturing footprint including R&D laboratories with clean room and prefilled syringe equipment at its Daegu headquarters, a sales/marketing office in Seongnam (Gyeonggi-do), and a newly completed specialty pharmaceutical GMP factory in Sejong (~16,528 sqm) supporting BIENOX and drug substance production. BNC holds domestic Korean patents on HA derivative particle manufacturing and on collagen wound dressings containing drugs/antibiotics, alongside CE, ISO 13485, ISO 9001, ISO 14001, ISO 22716, GMP, and KFDA/KMFDS certifications across product lines.

BNC KOREA generates revenue through four streams: (1) medical device sales via direct domestic B2B and international export; (2) OEM/ODM manufacturing for international partners under multi-year supply contracts, anchored by a US-based customer at minimum US$3M annually and a Chinese partner at 1 million units annually; (3) pharmaceutical product sales focused on BIENOX for aesthetic and therapeutic use; and (4) I.st cosmeceutical sales through its own e-commerce platform (istcosmetics.com). The company exports to approximately 45 countries across Europe, China, Latin America, the Middle East, India, and Southeast Asia, with export revenue rising from US$1M (2016) to US$5M (2018) Export Tower milestones. As of 2020, BNC employed 111 staff including 21 research personnel, with registered capital of approximately KRW 4.6 billion.

Name

BNC KOREA

Legal name

주식회사 한국비엔씨 (BNC KOREA, Inc.)

Website

https://bnckorea.co.kr

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

BNC KOREA is a Korean KOSDAQ-listed bio-venture that develops, manufactures, and exports hyaluronic acid and collagen-based medical devices, the BIENOX botulinum toxin pharmaceutical, and the I.st cosmeceutical brand to hospitals, clinics, OEM partners, and consumers across 45 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sales of proprietary medical devices including HA fillers (Cutegel, FLORE), anti-adhesion barriers (Hibarry), collagen wound dressings (GentaQ), and tissue supplements (Collapleo). Both domestic Korean market and international export sales through direct export and OEM partnerships.
2. OEM/ODM Export Manufacturing: Original equipment manufacturing agreements with international companies. Includes minimum annual supply contracts for dermal fillers (US$3 million+ annually to US company) and annual supply of 1 million units to Chinese partner.
3. Pharmaceutical Product Sales: Sales of specialty pharmaceuticals including BIENOX (botulinum toxin type A) for export markets and domestic Korean market. Professional pharmaceutical products requiring medical prescriptions.
4. Cosmeceutical Products (I.st Brand): Premium cosmetic line branded as I.st sold through company's online mall (istcosmetics.com). Includes skincare products across Premium, Special, Beauty Face, and Home Care lines.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

BNC KOREA is a Korean bio-venture company that develops, manufactures, and sells biomaterial-based medical devices, specialty pharmaceuticals, and cosmeceuticals. Core products include hyaluronic acid dermal fillers (Cutegel, FLORE, Juvegel), botulinum toxin type A (BIENOX), anti-adhesion barrier gel (Hibarry), collagen-based wound dressings (GentaQ) and tissue supplements (Collapleo), and the I.st premium cosmetic brand. The company operates GMP-certified manufacturing facilities and exports to 45 countries via OEM partnerships and local distributors.

Product overview

BNC KOREA is a Korean bio-venture company specializing in medical devices, pharmaceuticals, and cosmeceuticals. The product portfolio centers on hyaluronic acid-based dermal fillers (Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Juvegel), skin boosters (Cutegel Hydro, S-DNA, H-DNA, AQUABIEN HYDRO PURE, CELLABIEN I GLOWY), botulinum toxin (BIENOX), anti-adhesion barriers (Hibarry), collagen wound dressings and tissue supplements (GentaQ, Collapleo, Collapleo Plus), and the premium cosmeceutical brand I.st. The company operates with GMP-certified manufacturing facilities and exports to 45+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• I.st: Premium cosmetic brand by BNC KOREA offering skincare products including Premium Care Line, Special Care Line, Beauty Face Line, and Home Care Line.
• BIENOX
• Cutegel/FLORE
• Hibarry
• GentaQ
• Collapleo
• Juvegel

Quantifiable outcome

• Clinical safety and efficacy confirmed through comparative trials at major Korean university hospitals (Gacheon University Gil Medical Center, Gangnam Severance Hospital, Korea University Ansan Hospital, St. Vincent Hospital)
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• US-based Company AcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2017OEM export partnership for dermal filler supply. Contract for minimum US$3 million annually, with 5-year supply agreement valued at approximately KRW 155 billion (US$73 million for initial period). BNC manufactures dermal fillers for US company under their brand.
• China Company BcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2015Annual supply contract for 1 million units of dermal fillers to Chinese market. CFDA certification expected 2021 for market entry. Represents significant volume commitment for China market expansion.
• Local Partners in Emerging MarketsminorChannel Partner/ Reseller/ DistributorPartnerships with local distributors in Brazil, Middle East, India, and Indonesia for medical device registration and market development. Partners handle regulatory registration and local distribution of dermal fillers and anti-adhesion products.
• European Distribution Partners (Serbia, Bosnia, Poland)minorChannel Partner/ Reseller/ DistributorCE-certified dermal filler exports through distribution partners in Serbia, Bosnia, and Poland covering European market entry.
• Yonsei University College of DentistryminorStrategic or Co-development PartnerJoint research collaboration for developing treatment technology for jaw and facial bone regeneration using tissue-forming polypeptides.
• Daegu Catholic University School of MedicineminorStrategic or Co-development PartnerJoint research collaboration for developing treatment materials for retinal degenerative diseases using gold nanoparticle-labeled neovascular targeting nanocomplexes.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Hugel: Korean botulinum toxin (Botulax) and HA filler manufacturer. Closest direct competitor to BNC Korea in the domestic Korean aesthetic medicine market, with overlapping product categories (botulinum toxin, HA fillers) and global export ambitions.
• Medytox: Korean biopharmaceutical company developing botulinum toxin (Meditoxin/NeuBo) and HA-based dermal fillers. Direct competitor in both Korean domestic and international OEM markets for aesthetic injectables.
• Sinclair Pharma: UK-based aesthetic medicine company with HA filler (MaiLi) and collagen-stimulator portfolio. Comparable in scale and product focus to BNC Korea; similar OEM and global distribution model for aesthetic injectables.
• Croma-Pharma: Austrian aesthetic medicine company specializing in HA fillers, PRP, and botulinum toxin distribution. Comparable mid-sized European peer with similar product mix targeting global aesthetic medicine markets.
• Teoxane: Swiss HA dermal filler manufacturer with global distribution. Similar specialization in premium HA-based aesthetic products and similar international export model via local distributors.
• Revance Therapeutics: US aesthetics company developing botulinum toxin (Daxxify) and HA fillers. Comparable in scale and product focus, with similar OEM/licensing opportunities in select geographies.

Broad incumbents

• LG Chem (Life Sciences Division): Large Korean conglomerate with a life sciences division producing HA fillers (Yvoire) and other aesthetic/biomedical products. Much broader portfolio and greater resources than BNC Korea, but overlaps in core HA filler category.
• Daewoong Pharmaceutical: Major Korean pharmaceutical company with botulinum toxin (Nabota) and aesthetic medicine presence. Competes with BNC in Korea and selected export markets with established global distribution capabilities.
• Galderma: Global leader in dermatology and aesthetic medicine with Restylane, Sculptra, and Dysport franchises. Sets competitive benchmarks for HA fillers and botulinum toxin; broad incumbent rather than direct peer due to scale.

Regional players

• BioPlus (Collagen Wound Care): Korean biomaterials company producing absorbable collagen-based wound dressings and surgical implants. Direct peer in collagen wound dressing and tissue supplement categories overlapping with GentaQ and Collapleo product lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bnc-korea-inc

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BNC KOREA